jiayi-li23/proxann_data huggingface dataset:
Bill 114-HR-2709 — Health / R&D
Subject: Health

Professional's Access To Health Workforce Integration Act of 2015

Directs the Department of Health and Human Services, acting through the Bureau of Health Workforce within the Health Resources and Services Administration, the National Institute on Minority Health and Health Disparities, or the Office of Minority Health (HHS), to award grants to eligible entities to:

 provide services to assist unemployed and underemployed skilled immigrants residing in the United States, who have legal, permanent work authorization and who are internationally educated health professionals, in entering into and advancing in the American health workforce with employment matching their health professional skills, education, and expertise; provide training opportunities to reduce barriers to entry and advancement in the health workforce for skilled, internationally educated immigrants; educate employers regarding the abilities and capacities of internationally educated health professionals; assist in the evaluation of foreign credentials; and facilitate access to contextualized and accelerated courses on English as a second language. Includes as an eligible entity a clinical, public health, or health services organization, a community-based or nonprofit entity, an academic institution, a faith-based organization, a state, county, or local government, or an Area Health Education Center that submits an application that meets HHS requirements.

Defines "health professional" as an individual trained for employment or intended employment in specified fields, including public health, health management, dentistry, health administration, medicine, nursing, pharmacy, psychology, social work, psychiatry, and other mental and behavioral health, allied health, and community health or wellness work.
Bill 114-HR-2820 — Health / R&D
Subject: Health

(This measure has not been amended since it was reported to the Senate on December 3, 2015. The summary of that version is repeated here.)

Stem Cell Therapeutic and Research Reauthorization Act of 2015

(Sec. 2) This bill amends the Public Health Service Act and the Stem Cell Therapeutic and Research Act of 2005 to revise and extend through FY2020 the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory program. (These programs help match patients in need of a transplant with unrelated bone marrow and cord blood donors.)

The Department of Health and Human Services (HHS) must review the state of the science of using adult stem cells and birthing tissues to develop new therapies and consider the inclusion of new therapies in the C.W. Bill Young Cell Transplantation Program. (Sec. 3) Requirements for HHS contracts under the Stem Cell Therapeutic and Research Act of 2005 are revised.

(Sec. 4) HHS must determine whether to include peripheral blood stem cells and umbilical cord blood in the definition of human organ.
Bill 114-HR-2897 — Health / R&D
Subject: Health

Neglected Infections of Impoverished Americans Act of 2015

This bill requires the Department of Health and Human Services to report to Congress on the epidemiology of, impact of, and appropriate funding required to address neglected diseases of poverty, including Chagas disease, cysticercosis, toxocariasis, toxoplasmosis, trichomoniasis, soil-transmitted helminth infection, and other related diseases. The report should provide the information necessary to guide future health policy to evaluate the current state of knowledge concerning such diseases and address the threat of such diseases.
Bill 114-HR-2921 — Health / R&D
Subject: Health

Patients First Act of 2015

This bill amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to conduct and support basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of, or treatments for, diseases and other adverse health conditions, provided that the techniques will not involve: (1) the creation of a human embryo for research purposes; (2) the destruction or discarding of, or risk of injury to, a living human embryo; or (3) the use of any stem cell the derivation or provision of which would be inconsistent with this Act.

HHS must issue guidelines to ensure that any research (including any clinical trial) supported under this Act: (1) is clearly consistent with the standards established in this Act, if conducted using human cells; and (2) is prioritized in terms of potential for near-term clinical benefit in human patients.

HHS must report on peer reviewed stem cell research proposals that were not funded.
Bill 114-HR-2949 — Health / R&D
Subject: Social welfare

Treatment of Certain Payments in Eugenics Compensation Act

Excludes payments made under a state eugenics compensation program from classification as income or resources in determining eligibility for, or the amount of, any federal public benefit. Defines "state eugenics compensation program" as a state program for compensating individuals who were sterilized under the authority of the state.
Bill 114-HR-3033 — Health / R&D
Subject: Education

Research Excellence and Advancements for Dyslexia Act or the READ Act

(Sec. 3) This bill requires the National Science Foundation (NSF) to include in its annual congressional budget justification the amount requested for its Research in Disabilities Education program, which advances the goal of broadening the participation and achievement of learners with disabilities in science, technology, engineering, and mathematics.

(Sec. 4) Subject to the availability of appropriations, NSF must devote specified funding to support research on learning disabilities, including dyslexia, with the goal of practical application.
Bill 114-HR-3285 — Health / R&D
Subject: Health

Reducing Disparities Using Care Models and Education Act of 2015

This bill requires the Department of Health and Human Services (HHS) to contract with the National Academy of Medicine (formerly known as the Institute of Medicine) to study health disparities, existing programs and policies intended to reduce disparities, and priorities for, and expansion of, programs targeting disparities.

HHS must develop guidelines for entities to develop and implement programs to reduce health disparities. HHS must incorporate these guidelines into its activities.

HHS may award grants for programs to reduce health disparities.

The Innovation Center of the Centers for Medicare & Medicaid Services must test a payment and service delivery model that includes incentives for reducing health disparities.
Bill 114-HR-3498 — Health / R&D
Subject: Crime and law enforcement

Human Cloning Prohibition Act of 2105 

This bill amends the federal criminal code to prohibit human cloning for reproductive and research purposes.

Specifically, the bill makes it a crime for any public or private person or entity to:

 perform, attempt to perform, or participate in an attempt to perform human cloning; or ship, receive, or import a product of human cloning for any purpose. It defines "human cloning" as asexual reproduction by replacing a fertilized or unfertilized egg nucleus with a human somatic (body) cell nucleus to produce a living organism with a human or predominantly human genetic constitution.

A person or entity convicted of a human cloning offense is subject to a fine, up to 10 years in prison, or both. A person or entity who profits from such offense is also subject to a civil penalty of at least $1,000,000.

This bill does not restrict scientific research using nuclear transfer or other cloning techniques to produce molecules, DNA, cells other than human embryos, tissues, organs, plants, or animals other than humans.
Bill 114-HR-3658 — Health / R&D
Subject: Health

Gestational Diabetes Act of 2015 or the GEDI Act

This bill amends the Public Health Service Act to direct the Centers for Disease Control and Prevention (CDC) to develop a multisite gestational diabetes research project within the diabetes program of the CDC to expand and enhance surveillance data and public health research on gestational diabetes. 

The Department of Health and Human Services (HHS) must expand and intensify public health research on gestational diabetes, including; (1) developing and testing novel approaches for improving postpartum testing or screening and for preventing type 2 diabetes in women with a history of gestational diabetes, and (2) conducting research to further understanding of the factors and health systems that influence the risk of gestational diabetes and the development of type 2 diabetes in women with a history of gestational diabetes.

The CDC must: (1) award grants for demonstration projects to reduce the incidence of gestational diabetes, the recurrence of such disease in subsequent pregnancies, and the development of type 2 diabetes in women with a history of gestational diabetes; and (2) work with state and Indian tribal-based diabetes prevention and control programs assisted by the CDC to encourage postpartum follow-up after gestational diabetes to reduce the incidence of gestational diabetes and its recurrence, the development of type 2 diabetes in at-risk women, and related complications.
Bill 114-HR-3666 — Health / R&D
Subject: Health

Scleroderma and Fibrosis Research Enhancement Act of 2015

This bill requires the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to establish the National Commission on Scleroderma and Fibrosis Research. (Scleroderma and fibrosis are connective tissue conditions that cause hardening or scarring of skin and organs.)

The commission must develop a long-term, comprehensive plan for scleroderma and fibrosis research. The plan must: (1) prioritize research that has cross-cutting value and requires coordination across NIH, and (2) include specific steps for implementation of the research.

The commission must establish working groups to make research recommendations for the various organs and systems impacted by fibrotic illness.

The commission must be terminated not later than two years after establishment.

The NIAMS must create the Scleroderma and Fibrosis Working Group to oversee and assist with implementation of the long-term plan.
Bill 114-HR-3731 — Health / R&D
Subject: Health

Rare Disease Fund Act or the RaD Fund Act

This bill requires the National Institutes of Health (NIH) to organize the Rare Disease Therapeutics Corporation to purchase rights to, fund the development of, and sell ownership interests in drugs, biological products, and medical devices for rare diseases.

The NIH must sell stock in the corporation to investors as soon as practicable. The corporation and the NIH may enter into an agreement under which the NIH maintains an ownership interest in the corporation in exchange for providing the corporation with intellectual property or other assistance. The corporation is prohibited from paying dividends on its stock.

The corporation must sell its interest in a rare disease therapy prior to the therapy entering large-scale clinical trials.

The corporation must issue bonds guaranteed by the United States and may issue bonds backed by the corporation. For purposes of securities laws, the securities of the corporation are not issued or guaranteed by the federal government.

The bill establishes within the NIH the Rare Disease Therapeutics Corporation Science Advisory Council to advise the corporation on the purchase, sale, and development of rare disease therapies.
Bill 114-HR-3952 — Health / R&D
Subject: Health

Congenital Heart Futures Reauthorization Act of 2015

This bill amends the Public Health Service Act to replace the authorization for a National Congenital Heart Disease Surveillance System with a requirement for the Centers for Disease Control and Prevention (CDC), regarding congenital heart disease, to enhance and expand research and surveillance infrastructure, and plan and implement a public outreach and education campaign. (Congenital heart disease is a condition caused by a heart defect that is present at birth.)

The CDC must award grants to nonprofit entities to conduct: (1) a cohort study of congenital heart disease, from birth to adulthood, that considers health care utilization, demographic factors, and outcomes; and (2) an awareness, outreach, and education campaign regarding congenital heart disease.

The National Heart, Lung, and Blood Institute must report on its ongoing research efforts regarding congenital heart disease, future plans for such research, and areas of greatest need for such research.
Bill 114-HR-4400 — Health / R&D
Subject: Health

Adding Zika Virus to the FDA Priority Review Voucher Program Act

This bill amends the Federal Food, Drug, and Cosmetic Act to add the Zika virus to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)
Bill 114-HR-4625 — Health / R&D
Subject: Health

Firefighter Cancer Registry Act of 2016

This bill requires the Centers for Disease Control and Prevention (CDC) to develop and maintain a voluntary patient registry to monitor, collect, and make available epidemiological information related to cancer incidence and trends among firefighters. The CDC should seek to include specified information in the registry, including the number and type of fire incidents attended by an individual.

To collect information for the registry, the CDC may incorporate questions into existing public health surveys, questionnaires, and other databases.

The CDC must: (1) encourage the inclusion in the registry of data on minority, female, and volunteer firefighters; and (2) seek feedback on the registry from nonfederal experts.

The CDC must develop an approval process for making registry data available for research without a fee if findings or publications derived from the research are made public or available to stakeholders.
Bill 114-HR-4641 — Health / R&D
Subject: Health

(Sec. 1) This bill requires the Department of Health and Human Services to convene a Pain Management Best Practices Inter-Agency Task Force to: (1) review, modify, and update best practices for pain management and prescribing pain medication; and (2) examine and identify the need for, development of, and availability of medical alternatives to opioids (drugs with effects similar to opium, such as certain pain medications).

The task force must submit a report that includes: (1) the modified and updated best practices; (2) a strategy for disseminating the best practices; (3) the feasibility of linking the best practices to Drug Enforcement Administration registration of manufacturers, distributors, and dispensers of controlled substances; (4) recommendations for effectively applying the best practices at medical facilities; and (5) recommendations regarding medical alternatives to opioids.
Bill 114-HR-5073 — Health / R&D
Subject: Health

Ensuring Useful Research Expenditures is Key for Alzheimer's Act or the EUREKA Act

This bill amends the Public Health Service Act to require the National Institutes of Health (NIH) to establish EUREKA prize competitions to achieve high-priority breakthroughs in Alzheimer's disease and dementia prevention, diagnosis, treatment, and care.

The NIH must: (1) convene an advisory council of nongovernmental experts in Alzheimer's disease and dementia to develop the EUREKA prize competitions, and (2) appoint a panel of judges to evaluate submissions. The council and panel are not subject to the Federal Advisory Committee Act.

Support for EUREKA prize competitions may be provided by private organizations and individuals.
Bill 114-HR-5154 — Health / R&D
Subject: Crime and law enforcement

Fourth Amendment Integrity Restoration in Surveillance Act of 2016 or the F.A.I.R. Surveillance Act of 2016

This bill specifies that an agreement between a federal and state or local law enforcement agency regarding the acquisition or use of a cell simulator device must require such state or local law enforcement agency to use the device in compliance with the federal agency's guidance and policies.

The term "cell simulator device" means a device that: (1) simulates a cell tower to provide an electronic communication service, or (2) functions as a cell tower to locate cellular devices or identify their unique identifiers.
Bill 114-HR-5220 — Health / R&D
Subject: International affairs

Cyber Act of War Act of 2016

This bill directs the President to: (1) develop a policy for determining when an action carried out in cyberspace constitutes a use of force against the United States, and (2) revise the Department of Defense Law of War Manual accordingly.

In developing this policy, the President shall consider: (1) the ways in which a cyber attack's effects may be equivalent to a conventional attack's effects, including physical destruction or casualties; and (2) intangible effects of significant scope or duration.
Bill 114-HR-5249 — Health / R&D
Subject: Health

Safe Treatments and Opportunities to Prevent Pain Act or the STOP Pain Act

This bill authorizes the National Institutes of Health (NIH) to intensify and coordinate NIH research into the understanding of pain, therapies for chronic pain, and alternatives to opioids (drugs with effects similar to opium) for pain treatments.

The prioritization and direction of federally funded pain research must consider recommendations made by the Interagency Pain Research Coordinating Committee.
Bill 114-HR-5414 — Health / R&D
Subject: Health

FDA Cross-Center Collaboration Act of 2016

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish one or more Intercenter Institutes. Each institute must coordinate activities applicable to a major disease area among the FDA centers that review products. Activities may include coordinating staff with relevant expertise, streamlining product review, and enhancing interactions with patients, sponsors, and the biomedical community.
Bill 114-HR-5645 — Health / R&D
Subject: Health

United States-Israel Alzheimer's Disease Cooperation Act

This bill directs the Department of Health and Human Services (HHS) to establish a program of grants to support research on the development and commercialization of tools, treatments, and cures for Alzheimer's disease and other dementias. Supported projects must be joint ventures between U.S. and Israeli non-governmental entities or the U.S. and Israeli governments.

 HHS must establish an advisory board to monitor the method by which grants are awarded and to provide performance reviews of actions taken to carry out this bill.
Bill 114-HR-6185 — Health / R&D
Subject: Health

Ellie Helton, Lisa Colagrossi, Teresa Anne Lawrence, and Jennifer Sedney Focused Research Act or Ellie's Law

This bill authorizes the National Institute of Neurological Disorders and Stroke to conduct or support research on unruptured brain aneurysms in a patient population diversified by age, sex, and race.
Bill 114-HR-6224 — Health / R&D
Subject: Health

Enhancing Minority and Women Representation in NIH Medical Research Act of 2016

This bill amends the Public Health Service Act to require the National Institutes of Health (NIH), in assessing research priorities, to publish data on certain clinical research study populations. The NIH must foster collaboration among clinical research projects that use human subjects and that collect similar data to increase the number and diversity of subjects.

The strategic plans of the national research institutes must ensure that future activities take into account women and minorities and are focused on reducing health disparities. Advisory council reports must include certain demographic data for clinical research subjects. The results of NIH-funded clinical trials that include women and minorities must be submitted to NIH's clinical trial data bank.

The National Institute on Minority Health and Health Disparities may foster partnerships among the national research institutes and encourage the funding of collaborative research projects to achieve NIH goals related to minority health and health disparities.

The NIH must develop policies for NIH-funded basic research projects to assess how differences between male and female cells, tissues, or animals may be examined and analyzed.
Bill 114-S-43 — Health / R&D
Subject: Taxation

Ethical Stem Cell Research Tax Credit Act of 2015

Amends the Internal Revenue Code to allow a tax credit for 30% of qualified stem cell research expenses paid or incurred in a taxable year. Defines "qualified stem cell research expenses" as expenses for carrying out basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of or treatments for diseases and other adverse health conditions. Prohibits a tax credit for any research expenses that may involve: (1) the creation of a human embryo for research purposes; (2) the destruction of or discarding of, or risk of injury to, a human embryo; or (3) the use of any stem cell for prohibited purposes.
Bill 114-S-139 — Health / R&D
Subject: Health

This measure has not been amended since it was introduced. The expanded summary of the Senate-passed version is repeated here.) Ensuring Access to Clinical Trials Act of 2015 

(Sec. 2) This bill amends the Improving Access to Clinical Trials Act of 2009 to repeal the sunset of, and so extend indefinitely, the exclusion from resources under titles XVI (Supplemental Security Income) and XIX (Medicaid) of the Social Security Act, for eligibility purposes, of compensation in the amount of the first $2,000 per year received by individuals who participate in clinical trials for rare diseases or conditions.
Bill 114-S-276 — Health / R&D
Subject: Health

Collaborative Academic Research Efforts for Tourette Syndrome Act of 2015

Amends the Public Health Service Act to require the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH research on Tourette syndrome.

Requires the NIH to develop a system to collect data on Tourette syndrome, including epidemiological information, primary data, and data on the availability of medical and social services for individuals with Tourette syndrome and their families.

 Requires the NIH to award grants and contracts to public or nonprofit private entities to support four to six Collaborative Research Centers for Tourette Syndrome in different regions to conduct basic and clinical research on Tourette syndrome.

 Requires the NIH to award grants for research on the full range of symptoms within the Tourette syndrome clinical spectrum and the efficacy of treatment options for particular patient subpopulations.

Requires the NIH to designate a portion of the amounts made available to carry out NIH programs and activities for a fiscal year to carry out programs and activities with respect to Tourette syndrome.
Bill 114-S-289 — Health / R&D
Subject: Health

American Cures Act 

This bill amends the Balanced Budget and Emergency Deficit Control Act of 1985 to require certain adjustments to discretionary spending limits in FY2016-FY2021 to accommodate increases in appropriations for agencies that perform biomedical research. Adjustments are required for the National Institutes of Health, the Centers for Diseases Control and Prevention, the Department of Defense health program, and the Department of Veterans Affairs medical and prosthetics research program.

The bill also requires annual appropriations for each of the programs and agencies referenced in this bill to be at least the amount appropriated in FY2015.

The bill exempts appropriations provided pursuant to this bill from sequestration. Sequestration is a process of automatic, usually across-the-board spending reductions under which budgetary resources are permanently cancelled to enforce specific budget policy goals.